Literature DB >> 26044733

Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.

Hongyan Zhao1,2, Jianhong Gu1,2, Nannan Dai1,2, Qian Gao1,2, Dong Wang1,2, Ruilong Song1,2, Wei Liu1,2, Yan Yuan1,2, Jianchun Bian1,2, Xuezhong Liu1,2, Zongping Liu3,4.   

Abstract

This study aimed to investigate the effects of osteoprotegerin (OPG), a decoy receptor for receptor activator for nuclear factor κB ligand (RANKL), during the various stages of osteoclast differentiation, and additionally investigate its effects on osteoclast adhesion and activity. RAW264.7 murine monocytic cells were incubated with macrophage colony-stimulating factor and RANKL for 1, 3, 5, or 7 days, followed by an additional 24-h incubation in the presence or absence of OPG (80 ng/mL). We examined osteoclast differentiation and adhesion capacity using the tartrate-resistant acid phosphatase (TRAP) assay and immunofluorescence microscopy, and additionally examined cell growth in real time using the xCELLigence system. Furthermore, the expression levels of TRAP, RANK, integrin β3, matrix metalloproteinase 9, cathepsin K, carbonic anhydrase II, and vesicular-type H(+)-ATPase A1 were examined using western blotting. OPG exposure on day 1 enhanced the osteoclast growth curve as well as adhesion, and increased RANK and integrin β3 expression. In contrast, exposure to OPG at later time points (days 3-7) inhibited osteoclast differentiation, adhesion structure formation, and protease expression. In conclusion, the biological effects of OPG exposure at the various stages of osteoclast differentiation were varied, and included the enhanced adhesion and survival of preosteoclasts, the block of differentiation from the early to the terminal stages of osteoclastogenesis, and suppression of mature osteoclast activation following OPG exposure during the terminal differentiation stage, suggesting that the effects of OPG exposure differ based on the stage of differentiation.

Entities:  

Keywords:  Activation; Adhesion; Differentiation; Osteoclast; Osteoprotegerin

Year:  2015        PMID: 26044733      PMCID: PMC4960180          DOI: 10.1007/s10616-015-9892-7

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  39 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; H Tanaka; T Sasaki; T Nishihara; T Koga; T J Martin; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Tartrate-resistant acid phosphatase as a marker of bone resorption.

Authors:  C P Price; A Kirwan; C Vader
Journal:  Clin Chem       Date:  1995-05       Impact factor: 8.327

Review 5.  Advances in the regulation of osteoclasts and osteoclast functions.

Authors:  B F Boyce
Journal:  J Dent Res       Date:  2013-08-01       Impact factor: 6.116

6.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

Authors:  Claire M Shipman; Peter I Croucher
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

Review 7.  Osteoclast motility: putting the brakes on bone resorption.

Authors:  Deborah V Novack; Roberta Faccio
Journal:  Ageing Res Rev       Date:  2009-09-27       Impact factor: 10.895

8.  Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

Authors:  Simone H Mangan; Ann Van Campenhout; Catherine Rush; Jonathan Golledge
Journal:  Cardiovasc Res       Date:  2007-08-02       Impact factor: 10.787

9.  Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation.

Authors:  Michiyo Kobayashi-Sakamoto; Emiko Isogai; Kimiharu Hirose; Itsuo Chiba
Journal:  Microvasc Res       Date:  2008-07-04       Impact factor: 3.514

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more
  4 in total

1.  Characterizing how probiotic Lactobacillus reuteri 6475 and lactobacillic acid mediate suppression of osteoclast differentiation.

Authors:  Darin Quach; Narayanan Parameswaran; Laura McCabe; Robert A Britton
Journal:  Bone Rep       Date:  2019-11-02

2.  Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.

Authors:  Yonggang Ma; Xueni Shi; Hongyan Zhao; Ruilong Song; Hui Zou; Jiaqiao Zhu; Zongping Liu
Journal:  Int J Mol Med       Date:  2022-03-10       Impact factor: 4.101

Review 3.  A Review of Signaling Transduction Mechanisms in Osteoclastogenesis Regulation by Autophagy, Inflammation, and Immunity.

Authors:  Xishuai Tong; Gengsheng Yu; Xiaohui Fu; Ruilong Song; Jianhong Gu; Zongping Liu
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

4.  Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review.

Authors:  Nur Fathiah Mohd Radzi; Noor Akmal Shareela Ismail; Ekram Alias
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.